Novozymes, Inc.

Novozymes A/s

Other

Novo Nordisk A/s

Novo Nordisk Biotech, Inc.

Novozymes Biotech, Inc

Michael Lamsa

Janine Lin

Debbie Sue Yaver

Kim Borch

Shamkant Anant Patkar

Suzanne Otani

Barbara Cherry

Christopher Amolo

Allan Svendsen

Frank Winther Rasmussen

Matt Sweeney

Michelle Maranta

Doreen Bohan

Leslie Beresford

Mark Wogulis

Haiyan Ge

Ana Fidantsef

Elizabeth Znameroski

Signe Eskildsen Larsen

Lars Lehmann Hylling Christensen

Michael Skjoet

Peter Colin Gregory

Nina Lundin

Brian Gorre-Clancy

Lars Lehmann Christensen

Jesper Vind

Joel R Cherry

Howard Brody

Chritopher Amolo

Kim Hansen

Deborah S Yaver

Peter Kamp Hansen

Palle Schneider

Mads Eskelund Bjornvad

Jurgen Carsten Franz Knotzel

Anders Hjelholt Pedersen

Sarah Teter

Bjarne Gram Hansen

Connie Ward

Jürgen Carsten Franz Knötzel

Thomas Honger Callisen

Douglas J Boyle, Iii

Brian Gorre Clancy

Birger Rostgaard Jensen

Deborah Yaver

Douglas J Boyle Iii

Joel Cheery

Mads Eskelund Bjoernvad

Jürgen Carsten Franz KNÖTZEL

Callisen Thomas Honger Honger

Nina Vibeke Fabricius Lundin

The present invention relates to GH61 polypeptide variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.

GH61 variants and polynucleotides encoding same

GH61 polypeptide variants and polynucleotides encoding same

The pharmaceutical use of lipases related to the() lipase comprising amino acids 1-269 of SEQ ID NO: 2, optionally in combination with a protease and/or an amylase. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II. The lipases of the invention have, e.g., an improved digestion performance in vitro, an improved activity at a pH in the neutral range, an improved stability at low pH, an are stable against protease-degradation, and/or are stable in the presence of pepsin and bile salts. The invention also relates to methods of determining digestion performance in vitro of lipases, as well as to certain novel variants of the lipase of

Lipase variants for pharmaceutical use

The present invention relates to isolated polypeptides having lipase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.

Polypeptides having lipase activity and polynucleotides encoding same

The present invention relates to variants of a parent beta-glucosidase, comprising a substitution at one or more positions corresponding to positions 142, 183, 266, and 703 of amino acids 1 to 842 of SEQ ID NO: 2 or corresponding to positions 142, 183, 266, and 705 of amino acids 1 to 844 of SEQ ID NO: 70, wherein the variant has beta-glucosidase activity. The present invention also relates to nucleotide sequences encoding the variant beta-glucosidases and to nucleic acid constructs, vectors, and host cells comprising the nucleotide sequences.

Variants of beta-glucosidase

The present invention relates to methods for expression screening of filamentous fungal transformants, comprising: (a) isolating single colony transformants of a DNA library introduced into; (b) preparing DNA from each of the single colonytransformants; (c) introducing a sample of each of the DNA preparations of step (b) into separate suspensions of protoplasts of a filamentous fungus to obtain transformants thereof, wherein each transformant contains one or more copies of an individual polynucleotide from the DNA library; (d) growing the individual filamentous fungal transformants of step (c) on selective growth medium, thereby permitting growth of the filamentous fungal transformants, while suppressing growth of untransformed filamentous fungi; and (e) measuring activity or a property of each polypeptide encoded by the individual polynucleotides. The present invention also relates to isolated polynucleotides encoding polypeptides of interest obtained by such methods, to nucleic acid constructs, expression vectors, and recombinant host cells comprising the isolated polynucleotides, and to methods of producing the polypeptides encoded by the isolated polynucleotides.

Methods for transforming and expression screening of filamentous fungal cells with a DNA library

The pharmaceutical use of lipases related to the() lipase comprising amino acids 1-269 of SEQ ID NO: 2, optionally in combination with a protease and/or an amylase. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II. The lipases of the invention have, e.g., an improved digestion performance in vitro, an improved activity at a pH in the neutral range, an improved stability at low pH, and are stable against protease-degradation, and/or are stable in the presence of pepsin and bile salts. The invention also relates to methods of determining digestion performance in vitro of lipases, as well as to certain novel variants of the lipase of

Variants of beta-glucosidases

Growing community of inventors

Davis, CA, United States of America

Michael Lamsa